Cephalon Inc. Enters into Agreements with Barr Laboratories Inc. to Settle its Pending Patent Infringement Disputes in the United States.
Cephalon Inc. announced that it has entered into agreements with Barr Laboratories Inc. to settle its pending patent infringement disputes in the United States related to PROVIGIL(R) (modafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. In connection with the settlements, Cephalon will grant Barr a non- exclusive royalty-bearing right to market and sell a generic version of PROVIGIL in the United States. Barr's license will become effective in October 2011, unless Cephalon obtains a pediatric extension for PROVIGIL which would permit entry by Barr in April 2012. An earlier entry by Barr may occur based upon the entry of another generic version of PROVIGIL. Cephalon and Barr also agreed to a series of business arrangements related to modafinil. Specifically, Barr has agreed to grant to Cephalon a non- exclusive license, effective immediately, to certain of its worldwide intellectual property rights related to modafinil in exchange for an upfront payment. Cephalon also has agreed
